The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups
The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups
复制标题
依折麦布与他汀类药物联合治疗对不同患者组的疗效和安全性
DOI：
--
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
A. Tershakovec
中科院分区：
文献类型：
--
作者：
A. Catapano;P. Toth;J. Tomassini;A. Tershakovec
摘要各种胆固醇管理指南将降低低密度脂蛋白(LDL-C)作为降脂治疗(LLT)的主要目标，并将他汀类药物治疗作为降低LDL-C水平的重要途径。指南主张对没有达到推荐的低密度脂蛋白胆固醇水平的高危患者进行更强化的他汀类药物治疗和/或联合治疗。然而，许多人没有达到指南推荐的低密度脂蛋白水平，特别是那些心血管风险较高的人。对LLT的反应和耐受性也可能因患者特征而异，如年龄、性别和种族相关因素，以及包括糖尿病、代谢综合征、家族性高胆固醇血症、主动脉瓣狭窄和慢性肾脏疾病在内的医疗条件。对于有这些异常的患者，考虑这些特征对于优化LLT非常重要。在不同的患者群体中，胆固醇吸收抑制剂依折麦布与他汀类药物联合使用比单独使用他汀类药物更能改善低密度脂蛋白的降低、其他血脂参数和高敏感性C反应蛋白水平。联合用药还可以减少慢性肾脏疾病和主动脉瓣狭窄患者的缺血事件。在临床研究中，Ezetimibe加他汀类药物在6-24周内在22,000名患者中耐受性良好，在长达4年的研究中在>；11,000名患者中耐受性良好。这篇文章总结了心血管风险增加的亚组的治疗建议，并回顾了与依折替米布联合他汀类药物在这些和其他特定患者亚群中提供的有效性和安全性相关的现有信息。
Abstract Various guidelines for cholesterol management recognize LDL cholesterol (LDL‑C) lowering as the primary target of lipid‑lowering therapy (LLT) and statin therapy as an important approach to reducing LDL‑C levels. Guidelines advocate more intensive statin therapy and/or combination therapy for higher‑risk patients who do not achieve recommended LDL‑C levels. However, many individuals do not attain guideline‑recommended LDL‑C levels, particularly those at higher cardiovascular risk. Response to and tolerability of LLT can also vary by patient characteristics, such as age, gender and race‑related factors, as well as medical conditions including diabetes mellitus, metabolic syndrome, familial hypercholesterolemia, aortic valve stenosis and chronic kidney disease. Consideration of such characteristics is important in optimizing LLT for patients with these abnormalities. Coadministration of the cholesterol absorption inhibitor, ezetimibe, with statins improves LDL‑C lowering, other lipid parameters and high‑sensitivity CRP levels more than statins alone across diverse patient populations. The combination also reduces ischemic events in patients with chronic kidney disease and aortic valve stenosis. In clinical studies, ezetimibe plus statin therapy has been generally well tolerated in >22,000 patients during 6–24 weeks and in >11,000 patients in studies up to 4 years in duration. This article summarizes the treatment recommendations for subgroups at increased cardiovascular risk and reviews the available information relating to the efficacy and safety provided by ezetimibe in combination with statins in these and other specific patient subpopulations.
登录
查看更多内容
血脂异常的管理。
DOI：
10.1136/hrt.2005.071712
发表时间：
2006
期刊：
Heart (British Cardiac Society)
影响因子：
--
作者：
Paramsothy,Pathmaja;Knopp,Robert
通讯作者：
Knopp,Robert
DOI：
10.1056/nejmoa1001282
发表时间：
2010-04-29
期刊：
The New England journal of medicine
影响因子：
--
作者：
ACCORD Study Group;Ginsberg HN;Elam MB;Lovato LC;Crouse JR 3rd;Leiter LA;Linz P;Friedewald WT;Buse JB;Gerstein HC;Probstfield J;Grimm RH;Ismail-Beigi F;Bigger JT;Goff DC Jr;Cushman WC;Simons-Morton DG;Byington RP
通讯作者：
Byington RP
影响因子：
13.2
作者：
Coresh, J;Astor, BC;Levey, AS
通讯作者：
Levey, AS
影响因子：
13.6
作者：
Foley, RN;Murray, AM;Collins, AJ
通讯作者：
Collins, AJ
影响因子：
15.9
作者：
Temel, Ryan E.;Tang, Weiqing;Yu, Liqing
通讯作者：
Yu, Liqing